Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.489 +0.079 (+1.79%)
Streaming Delayed Price Updated: 10:13 AM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Via ACCESS Newswire
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Via ACCESS Newswire
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Via ACCESS Newswire
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Via ACCESS Newswire
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Via ACCESS Newswire
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
Via ACCESS Newswire
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Via ACCESSWIRE
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Via ACCESSWIRE
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Via ACCESS Newswire
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
Via ACCESSWIRE
CureVac to Present at the 12th International mRNA Health Conference
Via ACCESSWIRE
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Via ACCESSWIRE
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Via ACCESSWIRE
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Via ACCESSWIRE
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
Via ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Via ACCESSWIRE
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
Via ACCESSWIRE
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
Via ACCESSWIRE
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Via ACCESSWIRE
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
Via ACCESSWIRE
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Via ACCESSWIRE
CureVac Announces Voting Results of General Meeting
Via ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Via ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Via ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Via ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Via ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Via ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Via ACCESSWIRE
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.